Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.
Journal: EJHaem
Published: January 26, 2026
Metabolic rewiring and biomass redistribution enable optimized mixotrophic growth in Chlamydomonas.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 22, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Journal: American journal of hematology
Published: January 05, 2026
Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
Journal: American journal of hematology
Published: November 21, 2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 02, 2025
Disruption of acyl-acyl carrier protein (acyl-ACP) synthetase in cyanobacteria impairs lipid remodeling as revealed by acyl-ACP measurements.
Journal: Metabolic engineering
Published: June 17, 2025
Tocilizumab Dosing for Management of T Cell-Engaging Bispecific Antibody-Related CRS in Patients With R/R B-Cell NHL.
Journal: Clinical pharmacology and therapeutics
Published: January 15, 2025
Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.
Journal: Clinical and translational science
Published: December 20, 2024
Last Updated: 09/26/2026